Drugs / GSK1482160
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT00849134 Comparator | Nov 2008 → Apr 2009 | inflammatory disease | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK1482160 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00849134 ↗ |
| Known as | GSK1482160A | ChEMBL registry synonym — accepted as the source's own label CHEMBL1222883 ↗ |
| Action | Inhibit | “P2X purinoceptor 7 negative allosteric modulator” CHEMBL1222883 ↗1“GSK1482160 is a P2X7 receptor antagonist” NCT00849134 ↗ |
| Modality | Small molecule | — CHEMBL1222883 ↗ |
| Target | P2RX7 | “P2X purinoceptor 7 negative allosteric modulator” CHEMBL1222883 ↗ |